Eastell R, O’Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT et al (2016) Postmenopausal osteoporosis. Nat Rev Dis Primers 2:16069

Article  PubMed  Google Scholar 

Eftekhar-Sadat B, Ghavami M, Toopchizadeh V, Ghahvechi AM (2016) Wrist bone mineral density utility in diagnosing hip osteoporosis in postmenopausal women. Ther Adv Endocrinol Metab 7(5–6):207–211

Article  PubMed  PubMed Central  Google Scholar 

MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148(3):197–213

Article  PubMed  Google Scholar 

Magaziner J, Fredman L, Hawkes W, Hebel JR, Zimmerman S, Orwig DL et al (2003) Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol 157(11):1023–1031

Article  PubMed  Google Scholar 

Hallberg I, Rosenqvist AM, Kartous L, Lofman O, Wahlstrom O, Toss G (2004) Health-related quality of life after osteoporotic fractures. Osteoporos Int 15(10):834–841

Article  CAS  PubMed  Google Scholar 

Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20(10):1633–1650

Article  CAS  PubMed  Google Scholar 

Deng Y, Li L, Li C, Wang F, Qu Y (2020) Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis. Pak J Pharm Sci 33(1(Special)):495–498

PubMed  Google Scholar 

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104(5):1595–1622

Article  PubMed  Google Scholar 

Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84(7):632–637 (quiz 8)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95(9):4380–4387

Article  CAS  PubMed  Google Scholar 

Zhang JH, Xin HL, Xu YM, Shen Y, He YQ, Hsien Y et al (2018) Morinda officinalis How. - A comprehensive review of traditional uses, phytochemistry and pharmacology. J Ethnopharmacol 213:230–255

Article  CAS  PubMed  Google Scholar 

Liu ZW, Luo ZH, Meng QQ, Zhong PC, Hu YJ, Shen XL (2020) Network pharmacology-based investigation on the mechanisms of action of Morinda officinalis How. in the treatment of osteoporosis. Comput Biol Med 127:104074

Article  CAS  PubMed  Google Scholar 

Lin J, Lv T, Tian F, Wang Y, Wang M, Tang W et al (2018) Chinese herbal formulas for postmenopausal osteoporosis: a review of preclinical evidence on animal studies and molecular mechanism. Trad Med Mod Med 1(2):75–83

Article  Google Scholar 

Bao L, Qin L, Liu L, Wu Y, Han T, Xue L et al (2011) Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro. Chem Biol Interact 194(2–3):97–105

Article  CAS  PubMed  Google Scholar 

Wu PY, Chen W, Huang H, Tang W, Liang J (2022) Morinda officinalis polysaccharide regulates rat bone mesenchymal stem cell osteogenic-adipogenic differentiation in osteoporosis by upregulating miR-21 and activating the PI3K/AKT pathway. Kaohsiung J Med Sci 38(7):675–685

Article  PubMed  Google Scholar 

Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3–44

Article  CAS  PubMed  Google Scholar 

Fischer V, Haffner-Luntzer M (2022) Interaction between bone and immune cells: Implications for postmenopausal osteoporosis. Semin Cell Dev Biol 123:14–21

Article  PubMed  Google Scholar 

Ozaki Y, Koide M, Furuya Y, Ninomiya T, Yasuda H, Nakamura M et al (2017) Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. PLoS ONE 12(9):e0184904

Article  PubMed  PubMed Central  Google Scholar 

Ding Z, Shi H, Yang W (2019) Osteoprotective effect of cimiracemate in glucocorticoid-induced osteoporosis by osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa-beta ligand signaling. Pharmacology 103(3–4):163–172

Article  CAS  PubMed  Google Scholar 

Wiszniak S, Harvey N, Schwarz Q (2016) Cell autonomous roles of Nedd4 in craniofacial bone formation. Dev Biol 410(1):98–107

Article  CAS  PubMed  Google Scholar 

Xu K, Chu Y, Liu Q, Fan W, He H, Huang F (2022) NEDD4 E3 ligases: functions and mechanisms in bone and tooth. Int J Mol Sci 23(17):9937

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanpallewar S, Wang T, Koh DC, Quarta E, Fulgenzi G, Tessarollo L (2016) Nedd4-2 haploinsufficiency causes hyperactivity and increased sensitivity to inflammatory stimuli. Sci Rep 6:32957

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellavia D, Salamanna F, Raimondi L, De Luca A, Carina V, Costa V et al (2019) Deregulated miRNAs in osteoporosis: effects in bone metastasis. Cell Mol Life Sci 76(19):3723–3744

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartel DP (2018) Metazoan microRNAs. Cell 173(1):20–51

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lian JB, Stein GS, van Wijnen AJ, Stein JL, Hassan MQ, Gaur T et al (2012) MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol 8(4):212–227

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Y, Patil S, Qian A (2020) The role of microRNAs in bone metabolism and disease. Int J Mol Sci 21(17):6081

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Xue H, Tan G, Xu Z (2021) Effects of miRNAs, lncRNAs and circRNAs on osteoporosis as regulatory factors of bone homeostasis (Review). Mol Med Rep. https://doi.org/10.3892/mmr.2021.12428

Article  PubMed  PubMed Central  Google Scholar 

Mohamad N, Nabih ES, Zakaria ZM, Nagaty MM, Metwaly RG (2019) Insight into the possible role of miR-214 in primary osteoporosis via osterix. J Cell Biochem 120(9):15518–15526

Article  CAS  PubMed  Google Scholar 

Wang CG, Wang L, Yang T, Su SL, Hu YH, Zhong D (2020) Pseudogene PTENP1 sponges miR-214 to regulate the expression of PTEN to modulate osteoclast differentiation and attenuate osteoporosis. Cytotherapy 22(8):412–423

Article  CAS  PubMed  Google Scholar 

Wang C, Sun W, Ling S, Wang Y, Wang X, Meng H et al (2019) AAV-Anti-miR-214 prevents collapse of the femoral head in osteonecrosis by regulating osteoblast and osteoclast activities. Mol Ther Nucleic Acids 18:841–850

Article  CAS  PubMed  PubMed Central  Google Scholar